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Abstract
Angioimmunoblastic Lymphadenopathy with Dysproteinemia (AILD)
is a rare benign reactive process which often follows exposure to
certain drugs such as penicillin. Treatment with corticosteroids
usually reverses the process, however there have been reports of
18% of cases evolving into non-Hodgkins lymphoma. In our case
report, we present a relatively healthy woman with history of various
drug hypersensitivities who developed AILD and resultant lym
phoma after treatment with azithromycin.
A reviewofthe literature has failed to find reports ofAlLD following
macrolide exposure. Clonality, not present Th other forms of hyper
plasia, is present in AILD and immunosuppression may account for
this difference. It is difficult to say whether the drugs are simply
coincidently associated or actually cause, maintain, or exacerbate
clonality in AILD and facilitate malignant transformation.
Introduction
Angioimmunoblastic Lymphadenopathy with Dysproteinemia
(AILD) is a rare benign reactive process which often follows
exposure to certain drugs such as penicillin. It is characterized by
generalized lymphadenopathy, hepatosplenomegaly, and constitu
tional symptoms. Laboratory abnormalities include derangements
in blood counts and a polyclonal gammopathy. Hemolytic anemia
and morphologic bone marrow change are sometimes seen. Treat
ment with corticosteroids is typically successful in reversing the
process however there have been reports of 18% of cases evolving
into non-Hodgkins lymphoma. Evidence of clonality with subse
quent malignant transformation suggests a possible explanation for
drug association with AILD. We report a case ofangioimmunoblastic
lymphadenopathy without dysproteinemia evolving into T-cell lym
phoma following macrolide administration.
Case Report
History of Present Illness:
This 67y/o Japanese woman, with history of allergic rhinitis and
hypothyroidism diagnosed two months prior to admission, was
hospitalized one month prior to admission for new onset congestive
heart failure and atrial fibrillation with rapid ventricular response.
During this hospital stay, bilateral mastitis was noted with associ
ated tender axillary adenopathy and treated with azithromycin.
These resolved but follow-up two weeks later revealed generalized
lymphadenopathy and biopsies of left anterior cervical and right
inguinal nodes were taken. The local pathologist reported an
abnormal immune reaction versus Hodgkin’s and the specimens
were sent to Stanford University for an opinion. Throughout this
time the patient continued to suffer nausea, fatigue, appetite loss,
and a slight nonproductive cough and on the day of admission felt
extreme chills, shakes, and diaphoresis. She denied chest pain,
shortness of breath, headache, dizziness, photo- or phonophobia,
constipation, diarrhea, or symptoms of urinary tract or upper respi
ratory infection.
History:
No other medical or surgical history was significant. The patient
was allergic to amoxicillin, cephalexin, and donnatel with reactions
ranging from rash to difficulty breathing. She was on Synthroid,
Lasix, Digoxin, Plavix, and Cardizem. Family history was unre
markable except for her father who died of liver failure. She did not
have any tobacco, alcohol, or drug use, and denied travel and
exposure to animals or chemicals. She had up-to-date immuniza
tions and had received BCG vaccination, although her PPD was
negative. Recent mammogram was negative.
Physical Examination:
On exam, temperature was 105.2° and blood pressure was 143/63.
Left nostril occlusion was present with mucus and serosanguinous
drainage but without septal deviation and the oropharynx was moist
but erythematous without exudate. Diffuse, mobile, rubbery lymph
nodes 1-3 cm which were nontender and non-fluctuent were noted
especially in the right submandibular region. Neck was supple
without jugular venous distention. Lungs were clear except for
slight crackles and decreased fremitis in the right base. Breasts were
within normal limits. Heart was tachycardic and an S4 with grade
IIJVI systolic ejection murmur was present at the base. Mild
hepatosplenomegaly was present. No fecal occult blood was noted.
Good distal pulses and no clubbing, cyanosis, or edema were present
in the extremities.
HAWAB MEDEDAL JOURNAL, VOL 59. FEBRUARY 2000
John A. Burns School of Medicine
University of Hawaii
•‘Director of Medical Education
Kuakini Medical Center
Correspondence to:
Terence Y.J. Sasaki
3215 Ala Ilima St. 805B
Hon., HI 96818-2909
44
Laboratory Findings:
Laboratory investigations showed a white count of 12.1,28% bands,
and 12% monocytes. Hemoglobin and hematocrit were 10.4 and
30.7 respectively and electrolytes were normal except for bicarbon
ate at 31. Blood urea nitrogen and creatinine were 27 and 1.2.
Urinalysis contained 2+ blood and trace protein. Chest films
showed diffuse bilateral infiltrates at the bases while electrocardio
gram confirmed sinus tachycardia and revealed left atrial enlarge
ment and premature ventricular contractions. A “fever of unknown
origin” work-up was performed with negative blood cultures &
serologies and thyroid stimulating hormone was within normal
limits. C-reactive protein was 6.5.
Hospital Course:
Throughout her course, serologic studies, cultures, and immuno
electrophoresis continued to be unremarkable. Patient’s condition
improved slightly with empiric trovofloxacin but then deteriorated
into a sepsis-like picture on the third hospital day. The patient
needed to be transfused. Marrow aspirate showed only hyperplasia
of megakaryocytes. Preliminary node biopsy results from Stanford
suggested AILD and prednisone was initiated at 40mg BID and most
of her symptoms rapidly diminished. She continued to have residual
right submandibular lymphadenopathy. On day 12, routine exam
revealed a 3x2cm erythematous mass causing slight nasal septal
deviation and head CT and MRI showed an infiltrating left nasal
lesion which had biopsy findings consistent with lymphoma. Che
motherapy with Cytoxan and vincristine resulted in regression of the
lesion.
Discussion
First recognized by Flandrin and Westerhausen,”2
angioimmunoblastic lymphadenopathy with dysproteinemia (AILD),
a term coined by G. Frizzera in l974, is a rare benign reactive
process with a lymphoma-like presentation characterized by gener
alized lymphadenopathy, nontender hepatosplenomegaly, and con
stitutional symptoms. It was Lukes et al., however, who proposed
that AILD was associated with both benign and malignant forms.4
For the purposes of this discussion, AILD, immunoblastic lymphad
enopathy (IBL), and lymphogranulomatous X (LgX) have been
considered one entity, AILD (their differences are noted on table II).
Clinical Features
Generalized lymphadenopathy is the sine qua non of AILD and
these nodes often rapidly develop into soft, variably tender, mov
able, but not matted masses, measuring 2-3cm. Fever occurs in two
thirds and chills, night sweats, malaise, anorexia, and weight loss
give clue to the systemic nature of this entity. Peak incidence occurs
in the seventh and eighth decades. A prodrome of maculopapular
rash can be seen, without preferential location, in more than a third
of patients.5 It is commonly pruritic and follows administration of
drugs such as penicillin.2’68 Men are slightly predisposed, with a
1.2:1 ratio.5
Laboratory findings
In AILD, normochromic, normocytic anemia, particularly Coombs
positive and hemolytic, can be evident. Leukocytosis and eosino
philia may also complicate the picture. Dysgammaglobinemia,
most often a polyclonal hypergammopathy, is seen in up to three-
fourths of patients.’4 Low CD4 T-cell counts may be discovered
during active phases of the disease.’5 An elevated lactate dehydro
genase is present in 25-85%, often with accompanying hemolytic
anemja.’°’4
Findings % Patients
Anemia (autoimmune) 82 (45)
Lymphopenia/-cytosis 37/5
Leukocytosis 33
Neutrophilia/-penia 26/1
Plasma cells/immunoblasts 23
Thrombocytopenia 19
Eosinophilia 18
Monocytosis 13
Serological Profile of A1LD9 3
Findings % Patients
Dysgammaglobulinema
Polyclonal hypergammapathy 70
Hypogammaglobulinerna 7
Monoclonal component 5
Normal gammaglobulins 23
Positive Coombs test 39
Histological diagnosis
Marked proliferation of small vessels with hyperplastic endothe
hum and pleomorphic infiltrate rich in immunoblasts distributed in
an uneven pattern typify nodal biopsies. Pronounced and diffuse
obliteration of nodal architecture can be seen, with a third of victims
having some burnt-out germinal centers scattered across the field.
There is often sludgy, eosinophilic material between cells. Serial
nodal samples may show actual recovery of nodal architecture or
Clinical Findings at Presentation9’4
Findings % Patients
Lymphadenopathy 100
Generalized 81
Localized 21
Organomegaly
Liver 73
Spleen 63
Fever 74
Pruritis 48
Skin Rash 45
Peripheral Blood Findings in AILD9”’316
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extensive fibrosis.7Reactive morphological changes may be seen in
the spleen, bone marrow, liver, and skin but are usually less
prominent. The marrow aspirate may show mild plasmacytosis or
red cell hyperplasia, particularly in the setting of hemolytic anemia,
but will be normal in up to half of patients)7
AILD is distinguished from neoplasm because peripheral sinuses
and remnants of germinal centers are preserved, the angiocellular
changes doe not occur with any known malignant lymphoma, and
the end result in AILD is lymphocytic depletion with perivascular
fibrosis not tumoral replacement of organ structures. Surgical stag
ing is not recommended unless progression to lymphoma has
occurred. 19
Although rare, AIL-TCL account for 4% of all lymphomas (20%
of T-cell) by Kiel classification (table J)20 AILD-like lymphomas
are surprisingly similar to IBL-like lymphomas first described in
Japan.2122 Virtually all AILD-like lymphomas are peripheral T-cell
but rare B-cell lymphomas, often EBV associated, exist.23’7 Ex
panded FDC clusters & CD 21-positive reticulum cells surrounding
post-capillary venules have been found to be specific for AILD-like
lymphoma.4’2°
Dfferential diagnosis
Distinguishing collagen vascular disease, lymphoma, infection,
drug reaction, and graft-versus-host disease (GVHD) from AILD is
a diagnostic dilemna. Despite their shared constitutional and
clinical similarities, the vasculitis, renal assault, and epidermal skin
lesions that are prominent in SLE are absent in AILD.
Although malignant transformation is possible, there are several
contrasts between lymphomas and pure AILD. Clinically, rarely do
non-AILD-type lymphomas consistently display the generalized
lymphadenopathy, hepatosplenomegaly, and constitutional symp
toms which virtually define AILD. Histologically, lymphomas,
with scant vasculature, have monomorphic cellularity and atypia
which are features not found in AILD. Another difference are the
remnant germinal centers that persist in A1LD despite intense
cellular proliferation.
Histologically similar, differentiating AILD from reactive pro
cesses like infections, such as infectious mononucleosis and postviral
adenitis, or autoimmune disorders are important. Infections can
coexist with AILD, but nodal biopsy will differentiate the two.
Atypical clear cells are present in AIL-TCL, not infections.
Early AILD may have well-preserved germinal centers which
may be hard to distinguish from reactive hyperplasia or Castleman’ s,
making repeated biopsies useful. Molecular genetic analysis, with
DNA hybridization, and immunophenotyping are the best tech
niques available for diagnosis)3
In many respects, GVHD is clinically identical to AILD. The
generalized lymphadenopathy, hepatosplenomegaly, autoimmune
hemolytic anemia, susceptibility to infection, and constitutional
symptoms such as weight loss are all familiar to the GVHD picture.
Skin and hepatic lesions, however, are not nearly as prominent in
AILD and the history of organ transplant is noticably absent.
Histologically, the immunoblast proliferation, the disappearance of
follicular structures, eosinophilic deposits, and sometimes granulo
matous lesions are all mutually common in the nodes and spleen of
patients with both diseases. It is important to note, however, that
GVHD pathogenesis is very similar to that of AILD and AILD may
simply be an abnormal immune response with pharmaceutical and
not tissue triggers.
Prognosis and Treatment
A stormy and unpredictable course is standard and, seemingly
despite treatment modalities, a period of either rapid progression or
remission occurs with fatality in months to years.2”’9 Death occurs
in 75% of those affected with a median survival of 30 months.3°
About one third of patients respond to immunosuppressants)32
The presence of clear cells, age of onset, type of pharmacotherapy,
presence of clonality, and other factors have not been found to be
good prognostic indicators for AILD.’5’33 Complete remission after
steroid therapy, which occurs in up to 30%, best correlates with good
outcome whereas progression to malignant lymphoma, which occur
in l8-50%,°’ is associated with poor prognosis. Despite its “low
grade” revised Kiel classification, median survival is 16 months in
malignant transformation,23323536 with drug exposure, elevated lac
tate dehydrogenase. rash, and lymphocytopenia associated with
more rapid progression.3’ Therapy is controversial and can be as
conservative as support with steroids or as aggressive as multi-drug
combination chemotherapy, utilized particularly in cases with
HAWAW MEDICAL JOURNAL, VOL 59, FEBRUARY 2000
Table 1.— Classification of AIL-TCL18
Revised European American Lymphoma Peripheral T-cell and NK- cell neoplasm
(REAL) Classification
Rappaport Not listed (diffuse mixed lymphocytic-his
tiocytic, histiocytic)
Kiel T-cell, angioimmunoblastic (AILD)
Lukes-Collins IBL-like T-cell lymphoma
Working Formulation Not listed (diffuse mixed small and large-
cell, diffuse large cell, large cell
immunoblastic)
Table 2.— Morphological Criteria: Diagnosis of AILD, Immunoblastic
Lymphadenopathy (lBL), and Lymphogranulomatosis X (LgX)3’49”°”28
Common Findings
Diffuse obliteration of the lymph node architecture
Proliferation of small vessels (esp postcapillary venules)
Polymorphous cytology
Absence of florid germinal centres
Differences
Immunoblasts and plasma cells are abundant in AILD and IBL; in LgX either
immunoblasts, plasma cells, lymphocytes, or epithelioid cells may prevail
In IBL, the lymph node is lymphocyte-depleted and hypocellular
PAS-positive interstitial material is always present in IBL, but not in AILD and LgX
Burnt out germinal centres may occur in AILD and LgX, but not in IBL
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clonality.’°”7’37Case reports of successful treatment of AIL-TCL by
IFN-a, fludarabine, COPBLAM/IMVP-16, and 2-
chlordeoxyadenosine have so far been anecdotal.35’4°Infectious
complications are the most common cause of fatality, especially
pneumonia by CMV, P. carinii, and Aspergillus.’3’05 TMP-SMX
prophylactus may be considered.
Conclusion
In 70-95%, there is evidence of clonality even in early forms of
AILD, mostly in the T-cell recepter (TCR) gene)5’24354 IgH
rearrangement is also present in 10% of cases.’5 Serial biopsies have
shown either reduction in clones or malignant transformation’237
Researchers theorize that the initially benign hyperplasia may
simply promote clones with genetic rearrangements due to the
numerous rapidly repeating cell divisions.23 Clones, however, are
not present in amounts appreciable by Southern blot assay in other
forms of hyperplasia.23 Immunosuppression in AILD may account
for this difference as T-cell deficiency in regulation is known to
result in B-cell proliferation and autoaggression.5’42 The worst
prognosis is for those with complex uberrant clones and chromo
some ip structural defects, which is also found in other cancers.36
Allergies and drugs such as aspirin, phenytoin, halothane, L-dopa,
and antibiotics such as penicillins, tetracycline, and the sulfona
mides have been associated previous to onset ofAILD.35’7 A review
of the literature has failed to find reports of AILD following
macrolide exposure. In our case report, we present a relatively
healthy woman of typical age for the onset of the disorder with
allergic rhinitis and history of various drug hypersensitivities.
While statistical correlation points to the strong possibility that
pharmaceutical exposure may be a risk factor for subsequent devel
opment of AILD, the pathophysiologic theory of causation may be
more obscure. Some evidence suggests that certain B-cell aberra
tions are a result of drug hypersensitivity.4 It is difficult to say
whether the drugs are simply coincidently associated or actually
cause, maintain, or exacerbate clonality in AILD and if drug expo
sure causes AILD to be more likely to progress to frank lymphoma.
Only continuing research will bring light to this query.
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Figure 1.—Prominent blood vessel with extravasated blood in back
‘‘nlymphosytic.
Figure 2.— High power of endothelial proliferation within lymphoma
characteristic of AILD-like T-Cell lymphoma.
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percentage of OPCAB patients (15.9%) had greater than 3 grafts 
performed compared to the traditional CABG group (14.7%). 
Graft patency is an obvious important endpoint not addressed in 
this study. Surgeon selection bias (i.e. perhaps only patients with 
relatively larger target coronary vessels underwent OPCAB) also 
limits useful analysis. We believe that only a properly performed 
prospective randomized trial can adequately answer this question. 
Early angiographic results by others however, have been reported. 
Jansen et al7 in a favorable clinical report of their first 100 patients 
who underwent multivessel OPCAB documented an angiographic 
patency rate of 95%. Calafiore and colleagues in 190 consecutive 
patients and Subramanian in 52 consecutive patients have reported 
angiographic patency rates of 98.9%,8 and 96.2%,9 respectively. 
Not all patients can undergo OPCAB. Anatomic and hemody-
namic considerations play a role as well as the experience of the 
surgical team. In this series, 4 patients (5.5%) initially undergoing 
OPCAB were converted intraoperatively to a traditional CABG. In 
these patients, hemodynamic instability resulted from either lifting 
or stabilizing the heart, necessitating conversion. There were no 
myocardial infarctions or other significant complications in these 
patients. All were discharged home safely with total hospitaliza-
tions ranging from five to nine days (mean 6.5 days). In this study, 
these patients were included in the traditional CABG group for 
analysis. 
Because of these limitations, definitive conclusions regarding the 
role of the 0 PCAB in the general cardiac surgical population cannot 
be made. Surgeon selection bias can only be overcome with a 
prospective randomized clinical trial. We believe, however that 
these results are interesting and warrant further study. Accordingly, 
we have now embarked and are actively enrolling patients into a 
prospective randomized clini,cal trial comparing the OPCAB to 
traditional CABG. Funded by a grant from the Hawaii Community 
Foundation, we are studying the effects of the two procedures on 
neurologic function, morbidity and cost. Pre and postoperative 
neurologic and neurocognitive function, brain perfusion and intra-
operative Transcranial Doppler analysis of cerebral microemboli, 
are important facets of this ongoing clinical trial. 
We believe that the OPCAB is an exciting new procedure, which 
may have much potential. As with any new medical procedure 
however, careful and objective study in the context of a prospective 
randomized protocol should be encouraged. 
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